Yanbing Gong

Dr. Yanbing Gong


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
WZWenhua Zhang
Wenhua Zhang
SZShuwen Zhang
Shuwen Zhang
CDChenlu Dong
Chenlu Dong
SGShuaijie Guo
Shuaijie Guo
WJWeiyu Jia
Weiyu Jia
YGYanbing Gong
Yanbing Gong
Background: RNA methylation has emerged as an active research field in diabetes mellitus (DM) and its complications, while few bibliometric analyses have been performed. We aimed to visualize the hotspots and trends using bibliometric analysis to provide a comprehensive and objective overview of the current search state in this field.Methods: The articles and reviews regarding RNA methylation in DM and its complications were from the Web of Science Core Collection. A retrospective bibliometric analysis and science mapping was performed using the CiteSpace software to plot the knowledge maps and predict the hotspots and trends.Results: Three hundred seventy-five qualified records were retrieved. The annual publications gradually increased over the past 20 years. These publications mainly came from 66 countries led by Canada and 423 institutions. Leiter and Sievenpiper were the most productive authors, and Jenkins ranked first in the cited authors. Diabetes Care was the most co-cited journal. The most common keywords were “Type 2 diabetes”, “cardiovascular disease”, “diabetes mellitus”, and “n 6 methyladenosine”. The extracted keywords mainly clustered in “beta-cell function”, “type 2 diabetes”, “diabetic nephropathy”, “aging”, and “n6-methyladenosine”. N6-methyladenosine (m6A) in DM and its complications were the developing areas of study.Conclusion: Studies on RNA methylation, especially m6A modification, are the current hotspots and the future trends in type 2 diabetes (T2D) and diabetic nephropathy (DN), as well as a frontier field for other complications of DM. Strengthening future cooperation and exchange between countries and institutions is strongly advisable to promote research developments in this field.

15 September 2023 in World Journal of Diabetes
Verified
Journal Article
Open access
HLHong-Dian Li
Hong-Dian Li
MLMing-Xuan Li
Ming-Xuan Li
WZWen-Hua Zhang
Wen-Hua Zhang
SZShu-Wen Zhang
Shu-Wen Zhang
YGYanbing Gong
Yanbing Gong
Diabetes and associated complications represent major global public health issues which are associated with impaired quality of life and premature death. Although some diabetic complications have decreased in the developed world, the majority are still prevalent, with an increasing trend in the developing world. Currently used therapies are mainly ‘glucocentric’, focusing on the optimization of glycemic control to prevent, delay or manage diabetes-associated complications- other common comorbidities, such as dyslipidemia and hypertension are often underestimated. Although a number of novel therapeutic approaches have been reported recently, some of them have not received comparable attention in relation to either further studies or potential clinical implementation. This editorial briefly discusses some recent therapeutic approaches to the prevention and management of diabetes and its associated complications, as well as potential directions for future research and development in this area.

3 October 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
MWMaoying Wei
Maoying Wei
WMWenxin Ma
Wenxin Ma
WZWenhua Zhang
Wenhua Zhang
DYDan Yin
Dan Yin
YTYiting Tang
Yiting Tang
YGYanbing Gong
Yanbing Gong
Objective: To evaluate the efficacy and safety of Ophiocordyceps sinensis (OS) preparations for the treatment of Hashimoto’s thyroiditis (HT).Methods: We searched eight databases to collect randomized controlled trials (RCTs) of OS combined with a low-iodine diet or levothyroxine for HT. The search period was from inception to June 2023. Meta-analysis was performed using Revman 5.3 software after two evaluators independently screened the literature, extracted data, and evaluated the risk of bias of the included studies. The GRADE system was used to assess the certainty of evidence.Results: A total of 14 RCTs involving 1,014 patients with HT were included. Meta-analysis showed that OS preparations combined with a low-iodine diet were more effective in reducing thyroid peroxidase antibody (TPOAb) [SMD = −3.81, 95% CI (−5.07, −2.54), p < 0.00001] and thyroglobulin antibody (TgAb) [SMD = −4.73, 95% CI (−6.86, −2.61), p < 0.00001] compared to a low-iodine diet. Compared with levothyroxine treatment alone, OS preparations combined with levothyroxine further reduced TPOAb [SMD = −2.04, 95% CI (−2.82, −1.26), p < 0.00001], TgAb [SMD = −2.01, 95% CI (−2.68, −1.33), p < 0.00001], tumor necrosis factor alpha (TNF-α) [SMD = −3.40, 95% CI (−5.66, −1.14), p = 0.003], interleukin-2 (IL-2) [SMD = −2.31, 95% CI (−3.98, −0.65), p = 0.006], and interleukin-6 (IL-6) [MD = −4.16, 95% CI (−6.17, −2.15), p < 0.0001], and elevated free thyroxine (FT4) [SMD = 1.34, 95% CI (0.59, 2.08), p = 0.0004], but no significant effect on free triiodothyronine (FT3) [SMD = 0.83, 95% CI (−0.12, 1.78), p = 0.09] and thyroid stimulating hormone (TSH) [SMD = −0.80, 95% CI (−1.71, 0.11), p = 0.08]. In terms of safety, three studies reported adverse reactions in 10 patients in each of the experimental and control groups.Conclusion: OS preparations in combination with other treatments (low-iodine diet or levothyroxine) may decrease thyroid autoantibodies and inflammatory responses in patients with HT. In HT patients with hypothyroidism, the combination of the OS preparations with levothyroxine also improved FT4. However, the quality of the included studies was generally low. Moreover, the safety of OS preparations remains unclear. Therefore, more high-quality, multicenter, large-sample RCTs are needed in the future to validate the efficacy and safety of OS preparations.Systematic Review Registration:https://www.crd.york.ac.uk/prospero, identifier CRD42023432663

24 April 2025 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
YTYiting Tang
Yiting Tang
YCYupeng Chen
Yupeng Chen
YZYang Zhou
Yang Zhou
BWBingrong Wu
Bingrong Wu
SZShan Zhang
Shan Zhang
QNQing Ni
Qing Ni
Background: Type 2 Diabetes Mellitus (T2DM) poses a significant global health challenge, particularly among elderly adults. Dietary risk factors, such as high consumption of processed meats and sugar-sweetened beverages and low intake of whole grains and fruits, play a critical role in the burden of T2DM. This study aims to comprehensively quantify the global burden of T2DM attributable to dietary risks among elderly adults, identify significant dietary risk factors driving disease burden, and evaluate temporal, regional, and demographic variations to inform targeted public health strategies and interventions for reducing the impact of T2DM.Methods: This study utilized data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 to assess T2DM burden attributable to dietary risks among adults aged 65 years and older across 204 countries and territories. Metrics included age-standardized mortality rates (ASMR) and disability-adjusted life-year rates (ASDR). Dietary risk factors analyzed included low intake of whole grains, fruits, vegetables, and fiber, as well as high intake of processed meat, red meat, and sugar-sweetened beverages. Joinpoint regression and decomposition analyses were performed to examine temporal trends and drivers of changes by region, SDI level, sex, and age.Results: In 2021, dietary risks accounted for 23.61% of T2DM-related deaths and 24.85% of DALYs among elderly adults. ASMR showed a slight decline globally (AAPC: −0.08), while ASDR exhibited a significant upward trend (AAPC: +0.7) from 1990 to 2021. High SDI regions demonstrated decreasing ASMR but persistent DALYs due to prolonged survival with complications. Conversely, low and middle SDI regions exhibited rapid increases in ASMR and ASDR, driven by dietary transitions and limited healthcare resources. Males consistently bore a higher burden than females, with pronounced disparities in low and middle SDI regions. Aging and population growth were the primary drivers of the increasing burden globally.Conclusion: This study underscores the substantial burden of T2DM attributable to dietary risks among elderly adults and highlights significant regional and demographic disparities. Targeted public health interventions, personalized nutritional strategies, and improved healthcare access are essential to mitigate this burden. Future research should explore the impact of emerging dietary trends and precision nutrition on T2DM prevention and management.

27 March 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
JGJingyi Guo
Jingyi Guo
MWMaoying Wei
Maoying Wei
WZWenhua Zhang
Wenhua Zhang
YJYijia Jiang
Yijia Jiang
ALAijing Li
Aijing Li
YGYanbing Gong
Yanbing Gong
Objective: To investigate the safety and clinical efficacy of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and Finerenone in treating patients with type 2 diabetes mellitus (T2DM) combined with non-dialysis chronic kidney disease (CKD).Methods: Cochrane Library, PubMed, EMBASE, Web of Science, CNKI, CQVIP database, and WanFang from their inception up to November 2023 were searched to compare the efficacy and safety of SGLT-2 inhibitors, GLP-1 RA receptor agonists and Finerenone in the treatment of T2DM patients with non-dialysis CKD. To assess the methodological quality and risk of bias in the included studies, we utilized the Cochrane Risk of Bias Assessment tool (RoB 2.0). The confidence of evidence was examined using Confidence in Network Meta-Analysis (CINeMA). Traditional meta-analysis of variables was conducted using Stata 17.0 software with a random-effects model. We assessed publication bias using funnel plots and explored potential sources of heterogeneity through subgroup analysis.Results: A total of 39 studies (99,599 patients) were included. Compared to Placebo (PBO), SGLT-2 inhibitors demonstrated superior efficacy in reducing glycosylated hemoglobin (HbA1c) (MD = −0.33; 95%CI: from −0.52 to −0.15), systolic blood pressure (SBP) (MD from −5.52 to −1.50; 95%CI from −8.80 to −0.23), body weight (MD from −3.81 to −1.29; 95%CI from −6.34 to −0.84) and diastolic blood pressure (DBP) (MD = −1.86; 95%CI: −3.18, −40.54). The efficacy of Liraglutide in reducing Low-Density Lipoprotein Cholesterol (LDL-C) surpassed that of other agents (MD from −1.58 to −1.41; 95%CI from −2.05 to −0.81). Finerenone significantly reduced SBP (MD = −1.65; 95%CI: −2.48, −0.81) compared to PBO. According to the SUCRA based relative ranking of treatments, Empagliflozin was the most effective in reducing HbA1c and DBP. Semaglutide was the least harmful to estimated glomerular filtration rate. Liraglutide was the most effective in reducing LDL-C. Bexagliflozin, Canagliflozin were the most effective in reducing SBP and body weight. Finerenone had the lowest incidence of urinary tract infection, Hypoglycemia was the lowest in the Luseogliflozin group. Ertugliflozin was the least likely to cause acute kidney injury. Canagliflozin had the lowest probability of any adverse event.Conclusion: The safety of these drugs has been confirmed, except for some special drugs. SGLT-2 inhibitors had a preferential glucose-lowering and weight-loss function, GLP-1 receptor agonists had a preferential lowering of LDL-C and blood glucose, and Finereone significantly reduced SBP compared with PBO. Systematic Review Registration: PROSPERO, CRD42024571544.

5 March 2024 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
YJYijia Jiang
Yijia Jiang
WZWenhua Zhang
Wenhua Zhang
MWMaoying Wei
Maoying Wei
DYDan Yin
Dan Yin
YTYiting Tang
Yiting Tang
YGYanbing Gong
Yanbing Gong
Background: Type 1 diabetes mellitus (T1DM) has been associated with higher pulmonary tuberculosis (PTB) risk in observational studies. However, the causal relationship between them remains unclear. This study aimed to assess the causal effect between T1DM and PTB using bidirectional Mendelian randomization (MR) analysis. Methods: Single nucleotide polymorphisms (SNPs) of T1DM and PTB were extracted from the public genetic variation summary database. In addition, GWAS data were collected to explore the causal relationship between PTB and relevant clinical traits of T1DM, including glycemic traits, lipids, and obesity. The inverse variance weighting method (IVW), weighted median method, and MR‒Egger regression were used to evaluate the causal relationship. To ensure the stability of the results, sensitivity analyses assess the robustness of the results by estimating heterogeneity and pleiotropy. Results: IVW showed that T1DM increased the risk of PTB (OR = 1.07, 95% CI: 1.03–1.12, P < 0.001), which was similar to the results of MR‒Egger and weighted median analyses. Moreover, we found that high-density lipoprotein cholesterol (HDL-C; OR = 1.28, 95% CI: 1.03–1.59, P = 0.026) was associated with PTB. There was no evidence of an effect of glycemic traits, remaining lipid markers, or obesity on the risk of PTB. In the reverse MR analysis, no causal relationships were detected for PTB on T1DM and its relevant clinical traits. Conclusion: This study supported that T1DM and HDL-C were risk factors for PTB. This implies the effective role of treating T1DM and managing HDL-C in reducing the risk of PTB, which provides an essential basis for the prevention and comanagement of concurrent T1DM and PTB in clinical practice.